Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
The University of Sheffield has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 4 examiners and 4 art units, indicating distinct examination paths for each pending matter.
BENAVIDES, JENNIFER ANN is the busiest examiner, with 1 pending matter. Counsel should track each assignment independently and avoid relying on a common examiner or art unit approach.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
| BOSWORTH, KAMI A | 1 | 69.1% | +28.6% |
| ADLAM, CHANTAL PETA-GAYE | 1 | 53.5% | +27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779872 | GUIDING DEVICE FOR A VASCULAR CATHETER | BOSWORTH, KAMI A | 29d overdue |
| 18271980 | METHODS OF PREDICTING PROGRESSION OF NEUROLOGICAL DISEASE | NGUYEN, NAM P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17286797 | TREATMENT OF NEUROLOGICAL DISEASE | ADLAM, CHANTAL PETA-GAYE | 49d overdue |
| 17779872 | GUIDING DEVICE FOR A VASCULAR CATHETER | BOSWORTH, KAMI A | 29d overdue |
| 18286040 | PERIVASCULAR ACCUMULATION OF IMMUNE CELLS IN THE DIAGNOSIS AND TREATMENT OF CANCER | BENAVIDES, JENNIFER ANN | — |
| 18271980 | METHODS OF PREDICTING PROGRESSION OF NEUROLOGICAL DISEASE | NGUYEN, NAM P | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1678 | 1 |
| 3783 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286040 | PERIVASCULAR ACCUMULATION OF IMMUNE CELLS IN THE DIAGNOSIS AND TREATMENT OF CANCER | BENAVIDES, JENNIFER ANN | 1675 | §112Other | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18271980 | METHODS OF PREDICTING PROGRESSION OF NEUROLOGICAL DISEASE | NGUYEN, NAM P | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 12, 2023 |
| 17779872 | GUIDING DEVICE FOR A VASCULAR CATHETER | BOSWORTH, KAMI A | 3783 | §102§103 | Non-Final OA | 29d overdue | Pending | May 25, 2022 |
| 17286797 | TREATMENT OF NEUROLOGICAL DISEASE | ADLAM, CHANTAL PETA-GAYE | 1622 | §103DP | Final Rejection | 49d overdue | Pending | Apr 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe University of Sheffield has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Jennifer Ann Benavides has the most, with 1 of The University of Sheffield's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
